Surufatinib for high-risk NET after surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called surufatinib as an extra treatment after surgery for high-risk neuroendocrine tumors (NETs). It aims to see if taking surufatinib after surgery can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a neuroendocrine tumor (NET) that was surgically removed, and it is either Stage III G1/G2, any-stage G3, or considered high-risk by your doctor.
- Your blood counts, liver function, and kidney function are within certain ranges (your doctor will test these).
- You have not had major surgery, serious bleeding, or a blood clot in the last few months.
- You do not have poorly controlled high blood pressure or serious heart problems.
- If you could become pregnant, you must have a negative pregnancy test and use effective birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug surufatinib in people with advanced neuroendocrine tumors. It is a real-world study, meaning it looks at how the drug works in everyday practice, and may help control tumor growth.
This trial tests a combination of targeted therapy (Surufatinib) and chemotherapy (Temozolomide and S-1) as a first treatment for advanced neuroendocrine tumors that have not been treated before. It aims to see if this drug combo is safe and effective.
The purpose of this study is to see how well the medication surufatinib works and how safe it is for people with neuroendocrine tumours. They want to gather more information from a real-world setting to understand the benefits and side effects of this treatment.
This trial tests whether adding chemotherapy to the drug surufatinib works better than surufatinib alone for people with a rare type of lung cancer called pulmonary neuroendocrine tumor. If you have this diagnosis and haven't had prior systemic treatment, you may be eligible.
This trial tests a combination of targeted therapy (surufatinib), immunotherapy (serplulimab), and standard chemotherapy as a first treatment for advanced solid tumors that have neuroendocrine features. It aims to see if this combination can shrink tumors and improve outcomes for patients with certain cancers.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
Hear when a new Neuroendocrine Neoplasms (Tumours) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.